Abstract:

The pro-inflammatory cytokine Interleukin-6 (IL-6) –and T- T-cells play a major role in the pathogenesis and prognosis of many respiratory tract infections. Our study aimed to evaluate the role of T-Lymphocyte and IL-6 in Chronic Obstructive Pulmonary Disease (COPD) patients post-exposure to Tobacco or Tuberculosis. A cross-sectional prospective study was carried out from February 2021 to July 2022. Participants were enrolled at the Yaoundé Jamot Hospital. The intervention group comprised patients with post-TB/AFO (Tuberculosis/Airflow obstruction) and those with COPD related to tobacco, healthy subjects served as control. Spirometry results were obtained from the medical records. T-lymphocyte and IL-6 concentrations were measured by flow cytometry and ELISA (Enzyme-linked immunosorbent Assay) respectively. 150 participants were enrolled, 90 COPD patients and 60 healthy people. The COPD patients consisted of 50 with a history of smoking (COPD/tobacco) and 40 with a history of tuberculosis (post-TB/AFO). The level of IL-6 and CD4 cells (cluster differentiation) was higher in COPD patients compared to the control group (p-value 0.0001 and 0.0006 respectively). CD8 counts were higher in COPD/tobacco than in post-TB/AFO (p = 0.0043). IL-6 and CD4 were not statistically different between COPD/tobacco and post-TB/AFO. There was an inverse and non-significant correlation between IL-6 and CD8; and a non-significant positive correlation between IL-6 and CD4 with r = -0335, p = 0.087; R = 0.355; P = 0.069 respectively. IL-6 and CD8 T cells are involved in the pathogenesis of both COPD related to tobacco and post-TB airflow obstruction, with higher counts of blood CD8 cells in COPD/tobacco.

References:

[1] Daniel Lange, Casey E Ciavaglia, J Alberto Neder, Katherine A., Webb, and Denis E O’Donnell. Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications, and treatment. 10.1586/17476348.2014.949676 2014 Informa UK Ltd ISSN 1747-6348.

[2] GOLD: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2019. http://goldcopd.org/wp-content/uploads Accessed 10 April 2020.

[3] Roche N., Huchon G. Epidemiology of chronic obstructive pulmonary disease. Rev Prat., 2004, 54, 1408-1413.

[4] Pefura-Yone EW, Kengne AP, Tagne-Kamdem PE, Afane-Ze E. Clinical significance of low forced expiratory flow between 25% and 75% of vital capacity following treated pulmonary tuberculosis: a cross-sectional study. BMJ Open 2014; 4: e005361.

[5] Dina S., Shyamala G., Adam T.C., Meldrum C.A., Raja M., Adam M. G., Jeffrey L. C., Fernando J. M., Hershenson M.B., Umadevi S. Increased Cytokine Response of Rhinovirus-infected Airway Epithelial Cells in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med Vol 182. pp 332–340, 2010 DOI: 10.1164/rccm.200911-1673OC on April 15, 2010.

[6] Buist S. MD: Global Burden of COPD: risk factors, prevalence and future trends. the lancet 2007, 370:765-773.

[7] Gadgil A., Duncan S.R. Role of T-lymphocytes and pro-inflammatory mediators in the pathogenesis of chronic obstructive pulmonary disease. International Journal of COPD 2008:3(4) 531–541.

[8] Guiedem Elise, Mondinde Ikomey George, Nkenfou Céline, Pefura‑Yone Eric Walter, Mesembe Martha, Chegou Njweipi Novel, Graeme Brendon Jacobs, Okomo Assoumou Marie Claire. Chronic obstructive pulmonary disease (COPD): neutrophils, macrophages, and lymphocytes in patients with anterior tuberculosis compared to tobacco-related COPD. BMC Res Notes. 2018 ; 11 :192.

[9] Grubek-Jaworska H., Paplinska M., Hermanowiecz-Salamon J., Bialek-Gosk K., Dabrowska M., Grabczak E. IL-6 and IL-13 in induced sputum, of COPD and Asthma patients: correlation with respiratory tests. Respiration, 2012, 84(2), 7-101.

[10] Celli B., Locantore N., Yates J., Tal-Singer R., Miller B., Bakke P. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary diseases. Am J respir crit care Med., 185, 72-106572.

[11] Suleyman S.H., Hakan G., Levent C.M., Aysun B.K., Ismail T. Association between cytokines in induced sputum and severity of chronic obstructive pulmonary disease. 0954-6111. doi: 10.1016/j.rmed.2005.08.022.

[12] Hurst J.R., Perera W.R., Wilkinson T.M., Donaldson G.C., Wedzicha J.A. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173: 71-78

[13] Mallia P, Message SD, Contoli M, et al. Lymphocyte subsets in experimental rhinovirus infection in chronic obstructive pulmonary disease. Respir Med. 2014 ;108(1)78-85. doi: http://dx.doi.org/10.1016/j.rmed.2013.09.010.

[14] Gadgil A., Zhu X., Sciurba F., Ducan S. altered T-cell phenotypes in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006; 3:487–8.

[15] Mikhak Z, Farsidjani A, Luster AD. Endotoxin augmented antigen induced Th1 cell trafficking amplifies airway neutrophilic inflammation. J Immunol. 2009; 182(12): 7946-7956. doi: http://dx.doi.org/10.4049/jimmunol.0803522.

[16] Mustimbo E.P, Higgs BW, Brohawn P, Brohawn, Pilataxi F., Xiang G., Kuziora M., Bowler R.P., White W.I. CD4+ T-cell profiles and peripheral blood ex-vivo responses to T-cell directed stimulation delineate COPD phenotypes. J COPD F. 2(4): 268-280. doi: http://dx.doi.org/10.15326/jcopdf.2.4.2015.0131.

[17] Roberts MEP, Higgs BW, Brohawn P, et al. CD4+ T-cell profiles and peripheral blood ex-vivo responses to T-cell directed stimulation delineate COPD phenotypes. J COPD F. 2(4): 268-280.

[18] Dienz O., Eaton S., Bond J., Neveu W., Moquin D., Noubade R. The induction of antibody production by IL-6 is indirectly mediated by IL-12 produced by CD4+ T cells. J Exp Med., 2009, 206, 69-78.

[19] Dina S., Shyamala G., Adam T.C., Meldrum C.A., Raja M., Adam M. G., Jeffrey L. C., Fernando J. M., Hershenson M.B., Umadevi S. Increased
Cytokine Response of Rhinovirus-infected Airway Epithelial Cells in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med Vol 182. pp 332–340, 2010 DOI: 10.1164/rccm.200911-1673OC.

[20] Aubier M., Marthan R., Berger P., Chambellan A., Chanez P., Aguilaniu B. BPCO et Inflammation : mise au point par un groupe d’experts. Les mécanismes de l’inflammation et du remodelage. 0761-8425/S. doi : 10.1016/j.rmr.2010.10.004.

[21] Perez T., Mal H., Aguilaniu B., Brillet P.Y., Chaouat A., Louis R., Muir, J.-F. et al. BPCO et inflammation : mise au point d’un groupe d’experts. Les phénotypes en lien avec l’inflammation. 2010, 10.1016/j.rmr.